Business Description
Ipsen SA
ISIN : FR0010259150
Compare
Compare
Traded in other countries / regions
IPN.France0MH6.UKIPSEY.USAIPN.AustriaI7G.GermanyIPN.Mexico IPO Date
2020-05-12Description
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.73 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | 0.32 | |||||
| Interest Coverage | 15.66 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.41 | |||||
| Beneish M-Score | -2.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.2 | |||||
| 3-Year EBITDA Growth Rate | 3.8 | |||||
| 3-Year EPS without NRI Growth Rate | 7.8 | |||||
| 3-Year FCF Growth Rate | 2.7 | |||||
| 3-Year Book Growth Rate | 21.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 5.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.17 | |||||
| Quick Ratio | 0.99 | |||||
| Cash Ratio | 0.32 | |||||
| Days Inventory | 196.73 | |||||
| Days Sales Outstanding | 70.4 | |||||
| Days Payable | 461.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 6.3 | |||||
| Shareholder Yield % | 4.17 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.72 | |||||
| Operating Margin % | 17.85 | |||||
| Net Margin % | 19.49 | |||||
| FCF Margin % | 20.65 | |||||
| ROE % | 18.28 | |||||
| ROA % | 10.72 | |||||
| ROIC % | 10.26 | |||||
| ROC (Joel Greenblatt) % | 138.78 | |||||
| ROCE % | 17.95 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.81 | |||||
| Forward PE Ratio | 13.57 | |||||
| PE Ratio without NRI | 12.51 | |||||
| Shiller PE Ratio | 23.69 | |||||
| Price-to-Owner-Earnings | 13.41 | |||||
| PEG Ratio | 0.51 | |||||
| PS Ratio | 2.89 | |||||
| PB Ratio | 2.48 | |||||
| Price-to-Tangible-Book | 19.64 | |||||
| Price-to-Free-Cash-Flow | 13.97 | |||||
| Price-to-Operating-Cash-Flow | 11.02 | |||||
| EV-to-EBIT | 11.57 | |||||
| EV-to-EBITDA | 9.69 | |||||
| EV-to-Revenue | 2.8 | |||||
| EV-to-FCF | 13.54 | |||||
| Price-to-Projected-FCF | 0.97 | |||||
| Price-to-DCF (Earnings Based) | 0.35 | |||||
| Price-to-DCF (FCF Based) | 0.4 | |||||
| Price-to-Median-PS-Value | 0.96 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.51 | |||||
| Price-to-Graham-Number | 3.3 | |||||
| Earnings Yield (Greenblatt) % | 8.64 | |||||
| FCF Yield % | 7.21 | |||||
| Forward Rate of Return (Yacktman) % | 25.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ipsen SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 61,877.803 | ||
| EPS (TTM) (MXN) | 144.765 | ||
| Beta | -0.01 | ||
| Volatility % | 0.99 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (MXN) | 0 | ||
| 20-Day SMA (MXN) | 2285.02 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (MXN) | 2285.02 - 2285.02 | ||
| Shares Outstanding (Mil) | 82.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ipsen SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ipsen SA Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ipsen SA Frequently Asked Questions
What is Ipsen SA(MEX:IPN)'s stock price today?
The current price of MEX:IPN is MXN2285.02. The 52 week high of MEX:IPN is MXN2285.02 and 52 week low is MXN2285.02.
When is next earnings date of Ipsen SA(MEX:IPN)?
The next earnings date of Ipsen SA(MEX:IPN) is 2024-07-24.
Does Ipsen SA(MEX:IPN) pay dividends? If so, how much?
Ipsen SA(MEX:IPN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers